CN101594856A - Prevention and treatment contain the liquid of alcohol and the medicament and the method for the poisoning that pure succedaneum causes - Google Patents
Prevention and treatment contain the liquid of alcohol and the medicament and the method for the poisoning that pure succedaneum causes Download PDFInfo
- Publication number
- CN101594856A CN101594856A CNA2007800492983A CN200780049298A CN101594856A CN 101594856 A CN101594856 A CN 101594856A CN A2007800492983 A CNA2007800492983 A CN A2007800492983A CN 200780049298 A CN200780049298 A CN 200780049298A CN 101594856 A CN101594856 A CN 101594856A
- Authority
- CN
- China
- Prior art keywords
- poisoning
- medicament
- pure
- succedaneum
- ortho position
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 138
- 231100000572 poisoning Toxicity 0.000 title claims abstract description 90
- 230000000607 poisoning effect Effects 0.000 title claims abstract description 90
- 239000003814 drug Substances 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 59
- 230000002265 prevention Effects 0.000 title claims abstract description 17
- 239000007788 liquid Substances 0.000 title claims description 31
- 208000005374 Poisoning Diseases 0.000 claims abstract description 90
- 230000000694 effects Effects 0.000 claims abstract description 50
- 231100000331 toxic Toxicity 0.000 claims abstract description 49
- 230000002588 toxic effect Effects 0.000 claims abstract description 49
- 238000011161 development Methods 0.000 claims abstract description 23
- 241001597008 Nomeidae Species 0.000 claims abstract description 8
- 230000002829 reductive effect Effects 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims description 109
- 231100000614 poison Toxicity 0.000 claims description 104
- 230000007096 poisonous effect Effects 0.000 claims description 95
- 239000000203 mixture Substances 0.000 claims description 38
- 231100000419 toxicity Toxicity 0.000 claims description 35
- 230000001988 toxicity Effects 0.000 claims description 35
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 claims description 32
- 230000008569 process Effects 0.000 claims description 30
- 210000004185 liver Anatomy 0.000 claims description 29
- 230000006870 function Effects 0.000 claims description 25
- -1 previtamin Chemical class 0.000 claims description 25
- 102000004190 Enzymes Human genes 0.000 claims description 18
- 108090000790 Enzymes Proteins 0.000 claims description 18
- 239000013543 active substance Substances 0.000 claims description 16
- 210000000056 organ Anatomy 0.000 claims description 16
- 230000006378 damage Effects 0.000 claims description 13
- 238000002651 drug therapy Methods 0.000 claims description 12
- 239000002207 metabolite Substances 0.000 claims description 12
- 239000000729 antidote Substances 0.000 claims description 11
- 230000000968 intestinal effect Effects 0.000 claims description 11
- 238000001802 infusion Methods 0.000 claims description 10
- 239000002574 poison Substances 0.000 claims description 10
- 210000004072 lung Anatomy 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 7
- 210000003169 central nervous system Anatomy 0.000 claims description 7
- 238000001784 detoxification Methods 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 7
- 231100000774 toxicodynamics Toxicity 0.000 claims description 7
- 239000005515 coenzyme Substances 0.000 claims description 6
- 210000003240 portal vein Anatomy 0.000 claims description 6
- 231100000607 toxicokinetics Toxicity 0.000 claims description 6
- 210000001113 umbilicus Anatomy 0.000 claims description 6
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 231100000739 chronic poisoning Toxicity 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 229910021645 metal ion Inorganic materials 0.000 claims description 4
- 239000002858 neurotransmitter agent Substances 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 230000031018 biological processes and functions Effects 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 102000010911 Enzyme Precursors Human genes 0.000 claims description 2
- 108010062466 Enzyme Precursors Proteins 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 229910001413 alkali metal ion Inorganic materials 0.000 claims description 2
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 230000003907 kidney function Effects 0.000 claims description 2
- 230000003908 liver function Effects 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000008811 mitochondrial respiratory chain Effects 0.000 claims 1
- 210000003606 umbilical vein Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 208000037273 Pathologic Processes Diseases 0.000 abstract description 10
- 230000009054 pathological process Effects 0.000 abstract description 10
- 235000013334 alcoholic beverage Nutrition 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 7
- 230000008506 pathogenesis Effects 0.000 abstract description 7
- 231100000027 toxicology Toxicity 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 235000019441 ethanol Nutrition 0.000 description 114
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 53
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 33
- 150000001298 alcohols Chemical class 0.000 description 32
- 239000000463 material Substances 0.000 description 32
- 150000001299 aldehydes Chemical class 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 24
- FGGPAWQCCGEWTJ-UHFFFAOYSA-M sodium;2,3-bis(sulfanyl)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(S)CS FGGPAWQCCGEWTJ-UHFFFAOYSA-M 0.000 description 20
- 235000013361 beverage Nutrition 0.000 description 15
- 231100000167 toxic agent Toxicity 0.000 description 15
- 239000003440 toxic substance Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 10
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 9
- 230000001476 alcoholic effect Effects 0.000 description 9
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 229940046009 vitamin E Drugs 0.000 description 8
- 239000011709 vitamin E Substances 0.000 description 8
- 208000007848 Alcoholism Diseases 0.000 description 7
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 7
- 231100000570 acute poisoning Toxicity 0.000 description 7
- 201000007930 alcohol dependence Diseases 0.000 description 7
- 230000002605 anti-dotal effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000001647 drug administration Methods 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 230000003449 preventive effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 6
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 206010020565 Hyperaemia Diseases 0.000 description 6
- 208000002720 Malnutrition Diseases 0.000 description 6
- 229930003427 Vitamin E Natural products 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003792 electrolyte Substances 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 230000001071 malnutrition Effects 0.000 description 6
- 235000000824 malnutrition Nutrition 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 208000015380 nutritional deficiency disease Diseases 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 6
- 235000019165 vitamin E Nutrition 0.000 description 6
- 208000010444 Acidosis Diseases 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 231100000816 toxic dose Toxicity 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010027417 Metabolic acidosis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 229910052785 arsenic Inorganic materials 0.000 description 3
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000016072 chemical homeostasis Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000000254 damaging effect Effects 0.000 description 3
- 230000001066 destructive effect Effects 0.000 description 3
- 229960001051 dimercaprol Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 210000000107 myocyte Anatomy 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- QPRQEDXDYOZYLA-UHFFFAOYSA-N 2-methyl-1-butanol Substances CCC(C)CO QPRQEDXDYOZYLA-UHFFFAOYSA-N 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 2
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000013038 Hypocalcemia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 2
- 230000007950 acidosis Effects 0.000 description 2
- 208000026545 acidosis disease Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000002498 deadly effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 150000004662 dithiols Chemical class 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 210000003677 hemocyte Anatomy 0.000 description 2
- 229940000351 hemocyte Drugs 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000000705 hypocalcaemia Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000035806 respiratory chain Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- ACTRVOBWPAIOHC-XIXRPRMCSA-N succimer Chemical compound OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- QPRQEDXDYOZYLA-YFKPBYRVSA-N (S)-2-methylbutan-1-ol Chemical compound CC[C@H](C)CO QPRQEDXDYOZYLA-YFKPBYRVSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 206010001605 Alcohol poisoning Diseases 0.000 description 1
- 206010053164 Alcohol withdrawal syndrome Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010018873 Haemoconcentration Diseases 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 208000003085 Water-Electrolyte Imbalance Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 description 1
- QDPMLKBAQOZXEF-UHFFFAOYSA-N ethanesulfonic acid;sodium Chemical compound [Na].CCS(O)(=O)=O QDPMLKBAQOZXEF-UHFFFAOYSA-N 0.000 description 1
- ZRSDQBKGDNPFLT-UHFFFAOYSA-N ethanol;oxolane Chemical compound CCO.C1CCOC1 ZRSDQBKGDNPFLT-UHFFFAOYSA-N 0.000 description 1
- SKGZCJSZUWXMFE-UHFFFAOYSA-N ethanol;sulfurous acid Chemical compound CCO.OS(O)=O SKGZCJSZUWXMFE-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003944 halohydrins Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 231100000567 intoxicating Toxicity 0.000 description 1
- 230000002673 intoxicating effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000000639 membranetropic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 108010033145 microsomal ethanol-oxidizing system Proteins 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003864 performance function Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- YYMWVZQRBNARFZ-UHFFFAOYSA-M sodium;2-[2,3-bis(sulfanyl)propoxy]ethanesulfonate Chemical compound [Na+].[O-]S(=O)(=O)CCOCC(S)CS YYMWVZQRBNARFZ-UHFFFAOYSA-M 0.000 description 1
- 229940126589 solid medicine Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229960003196 unithiol Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 230000008320 venous blood flow Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to medicine, and can be used for developing medicine and method, it is used for the toxicology practice, and is used at home by the people, to prevent and to reduce the risk of dangerous disease (poisoning that the toxic component in for example pure succedaneum and the alcoholic beverage causes).The present invention is based on the purposes of the known compound of ortho position ethylene dithiol alcohols form.They are used to new purpose, promptly are used to develop medicament, and the character of this medicament can be prevented it, treats the pathological process that is produced by pure succedaneum poisoning or reduced speed.Medicament of the present invention reduces or blocks the pharmacological effect of ethanol and its derivant, and promptly the pathogenesis to the development of poisoning produces direct effect.Described medicament is the most effective when oral administration.Also disclose the test data project, it has proved that medicament of the present invention and prevention method can be widely used in the future, and described method is included in drinks before low quality alcopop and the pure succedaneum and take described medicament afterwards.The quantity that purposes of the present invention makes the poisoning that minimizing causes by succedaneum becomes possibility with the toxic action that reduces the seriousness of poisoning and consume alcopop at home.
Description
Technical field
The present invention relates to field of medicaments, and relate to the medicine that is used for the toxicology practice, and also relate to the medicine that is being used as preventive under the family's use alcoholic beverage situation that relates to the poisoning risk comprising.
The poisoning quantity relevant with alcopop (no matter being deliberately to take or accidental taking) that always increases and abuse pure succedaneum and just becoming serious medical treatment and social problem with voluntary use alcoholic beverage.According to official's data, only annual in the Russian Federation just have thousands of people death owing to such poisoning.Usually, medically Deng Ji poisoning case is always by using some poisonous substance and ethanol to cause, and beverage is because its inadequate purification quality, or do not plan to be used as esculent on the whole, usually contains these poisonous substances.Increase alcohol toxicity when known non-ethanol alcohol additive uses in the composition of beverage, described beverage is allowed to consumption usually.
The present invention relates generally to the ways and means that development is used for solving the problem of this area.
Background technology
In order clearly to understand hereinafter, this paper describes the term that uses in the field of the invention.
Alcohols (or alcohol type) is a hydrocarbon derivative, replaces hydrogen atom by hydroxyl (OH) and forms.Term used herein " alcohols " should be understood that the alcohol of any kind of: monoatomic or polyatomic, aliphatic or alicyclic, have the carbochain of any length or any available isomer.This class alcohol also can be represented in term " alcohol ", and it has different functional groups, promptly amino alcohol, halohydrin, sulfo-pure and mild other.
This paper also will discuss the ether of many alcohol, for example cellosolve.
On the whole, according to the disease International Classification (ICD) that The World Health Organization (WHO) accepts, the 10th revision (ICD-10), the poisoning of thinking in the present invention is meant the XIX class, T-51, T-52 group.
Typical poisonous substance (poisoning by its generation will be discussed in the present invention), following specifically material:
1. unary alcohol (alkane alcohols)
Methylol (methanol, carbinol, another name for) CH
3OH;
According to ICD-10, its toxic action is classified as the T-51.1 group;
Ethyl alcohol (ethanol, ethanol) C
2H
5OH; In the present invention, ethanol is not considered to self dependency poisonous substance, but unites with other poisonous substance, and its toxic action is increased and changes especially, and in this case, the poisoning that is caused by ethanol when with other poisonous substance associating is proved to be to be contained by field of the present invention; According to ICD-10, its toxic action is classified as the T-51.0 group;
Propyl group alcohol (normal propyl alcohol, isopropyl alcohol or the third-2 alcohol, or secondary propanol specifically; Isopropyl alcohol, high ethanol (perspirit)) C
3H
7OH;
According to ICD-10, its toxic action is classified as the T-51.2 group;
Butyl alcohols (one-level n-butyl alcohol or fourth-1 alcohol, or normal-butyl carbinol; Secondary n-butyl alcohol, or fourth-2 alcohol, one-level isobutanol, the tert-butyl alcohol) C
4H
9OH;
According to ICD-10, its toxic action is classified as the T-51.3 group;
Amyl group alcohols (amount to 8 isomers, wherein the most practical is n-pentyl alcohol, or penta-1 alcohol, or the normal-butyl carbinol) C
5H
11OH;
According to ICD-10, its toxic action is classified as the T-51.3 group.
2. di-alcohols (glycols, alkane glycols):
Ethylene glycol (ethylene glycol-1,2) CH
2OHCH
2OH;
Propylene glycol (propylene glycol-1,2) CH
3CHOHCH
2OH;
According to ICD-10, its toxic action is classified as the T-52.3 group.
3. polyhydric alcohol:
(oxolane ethanol, tetrahydrofuran base alcohol); CHCHCHC (OH) CH
2O
According to ICD-10, its toxic action is classified as the T-51.8 group.
Other toxic action that is suitable for poisonous substance of the present invention is classified as T-51.8 and T-51.9 and T-52 group (all according to ICD-10).
Poisonous substance mentioned above is as follows in the extensive fields of commercial Application:
Methanol is used for coating and varnish industry, also is used for alcoholic acid degeneration.
Ethanol is used to produce alcoholic beverage (and this is the main meaning of this paper) in extensively multiple commodity.
Isopropyl alcohol is used to produce antifreezing agent.Propanol is as the solvent of synthetic resin, quintessence oil etc.
Butanols is used to produce hydraulic fluid, in different organic synthesiss of a lot of industry neutralizations etc. also as solvent.
The one-level n-amyl alcohol is the basis that is called as Alcohols,fusel, and described Alcohols,fusel looks like a kind of oil-based liquid, is the mixture of the distillation end-product of alcoholic culture propagation product.
Tetrahydrofurfuryl alcohol also is used for different organic synthesiss as antigraining agent.
From the viewpoint of chemistry, when using the zymase fermentation, producing ethanol by the culture propagation of sugar is the catalysis multistep sugar decomposition process that forms pure and mild carbon dioxide.In order to guarantee zymic life cycle, with biologically available nitrogen and phosphorus source add the liquid solution (or brewing material (brew)) of being fermented, this certainly leads to some other primary alcohol outside the ethanol: methanol, propanol, isobutanol and isoamyl alcohol, optional active-amyl alcohol (2-methyl butanol-1).Except first kind, they all are collectively referred to as Alcohols,fusel.Except alcohols, in brewing material, together exist the composition of so-called volatility mixture to comprise aldehydes, acids and ethers with ethanol.In fact the fact that is worth believing is, in the distillation and fractional distillation process of the alcohol water blend that produces, is impossible with ethanol water from other alcohols and the complete purification of some other volatility mixture.Simultaneously, the quality of the final ethanol water that is obtained is by quality (its content is few more, and the quality of end-product is high more) and its composition decision of other residual alcohols.In addition, end-product comprises a certain amount of aldehydes that forms simultaneously during the fermentation inevitably.Essential consideration, a lot of alcoholic beverage do not distill (for example medicated beer) after fermentation.
Therefore, should consider, under many circumstances, by certain individual biology being used some simultaneous toxicity mixture and other toxicity mixture and its metabolite that exists with the form of other alcohols, its aldehydes and ethers, take alcoholic beverage and follow the poisoning that causes by ethanol itself and its metabolite.
Term " pure succedaneum " (AS) is understood that to allow the unsuitable substitute of the alcoholic beverage consumed.Conditionally, this term can comprise two class beverages: the first kind comprises beverage based on drinkable ethanol (this beverage does not have experience to be enough to obtain the purification process of standard quality), or based on the liquid (being called as " really " succedaneum) of industrial alcohol; Second class comprises and does not contain alcoholic acid or contain the liquid of the mixture of the ethanol of special preparation and other hydro carbons (comprising alcohols and/or its derivant).
The first kind is particularly including following material:
Hydrolysis ethanol and sulphite ethanol (ethanol that produces by the hydrolysis of timber);
Denatured alcohol (with methanol and the blended industrial alcohols of aldehydes)
Rough alcohol (contains ethanol and Alcohols,fusel through fermentation: the distillage of the biomass of propanol, butanols, amylalcohol and other alcohols and its isomer);
Gulong perfume, lotion, other spice and cosmetics liquid (alcoholic solution that contains the additive of quintessence oil and/or heterogeneity);
With ethanol inferior is the adulterated alcoholic beverage of basis preparation.
Polishing liquid (mixture of industrial alcohol and butanols, amylalcohol, chloroform, acetone etc.);
Different liquid (glue class, lacquer etc.).
Second class is particularly including following material:
Alcohol type (comprising ethanol);
Aldehydes, ketone;
The alcohol ethers;
The derivant of the chemical compound that above specifies;
The chemical compound of above stationery body explanation is the industrial liquid of basis preparation.
The feature of the poisoning that AS causes is that converted product biology of the original poison in biology is proved usually has the toxicity stronger than parent compound.Specifically, methanol, ethylene glycol and its ether, pure and mild other of tetrahydrofurfuryl are considered to the lower material of the original toxicity of this class.Material with these character usually is called as easily toxigenous (toxifiable), and described process itself is called as " toxic poisoning ", this means the formation material feasibility more malicious in metabolic process than natural poisonous substance, and the character and the seriousness of its amount influence poisoning in this case.According to alternative terminology, conversion process biology of this natural poisonous substance is known as " lethal is synthetic ".
In the present invention, the term poisonous substance is represented at least a material that is selected from down group:
Alcohol (not being ethanol or ethanol);
01 derivatives;
The alcohol succedaneum,
Poison (or poisoning) be the pathologic state that causes unusually by chemical homeostasis, described chemical homeostasis is caused by the interaction of the toxicant of the different biochemical structures of biology and exogenous origin or endogenous origin unusually.The process of poisoning completely represented in term " poisoning ", it begins development from its very primary symptom, up to the comprehensive clinical module of disease, its content depends on the toxic physiologic function of major receptors, promptly with interactional some biochemical structure of this poisonous substance (poison) selectivity.Different with endointoxication, heterointoxication is commonly called poisoning, and is relevant according to himself metabolism accumulation (self poisoning) in biological with toxicant.
Poisoning as the classification of chemical etiology disease based on 3 guidelines: pathogeny principle, clinical principle and nosonomy principle.
From the viewpoint of pathogeny principle, the poisoning that the present invention discusses:
According to reasons of development, be classified as accidental and/or deliberate;
According to origin, as a principle, be classified as family, be classified as industry more singularly;
Enter biological approach according to poisonous substance and be classified as dosage forms for oral administration, seldom insight is classified as suction, also more singularly-and transdermal delivery;
Origin according to poisonous substance is classified as heterointoxication.
According to the general modfel of development, process and the termination of poisoning, the toxic poisoning of discussing among the present invention can be following poisoning:
Acute, promptly after the toxicant single administration was given biology, clinical poison mode took place with quick and intensive process, rehabilitation or death during termination;
Subacute, promptly after poisonous substance single (or in one period short time several times) was administered to biology, the clinical development of poisoning was carried out in the mode of slowing down, and caused the greater or lesser persistence damage to health;
Chronic, this class poisoning feature is usually with little inferior toxicity dosage, repeatedly, has systemic feature, or the poisonous substance of using intermittently gives biologically, and it follows the symptomatology of its effect that continues and persistent damage to health naturally, and the latter increases and worsens periodically;
Subchronic, such poisoning and chronic poisoning difference are that the persistent period during its poisonous substance is used is shorter, and this is usually to weigh over the week or the moon.
According to the degree of seriousness, the poisoning of this paper discussion can be classified as follows:
Slight, medium serious, serious or lethal.
In the present invention, term " poisoning " is understood that any attainable poisoning that above specifies of being caused by any poisonous substance mentioned above.
The poisoning etiology factor of discussing is alcohols and/or its derivant, or other is with the poisonous substance of toxic concentration accumulation in biological, it can cause chemistry homeostatic unusual, promptly destroy the balance of the natural system of antidotal, described system is intended to the toxicant of biology from multiple origin purified out.
The pathogenesis of the poisoning that alcohols and pure succedaneum (AS) cause is analyzed by following two main aspects:
Toxicokinetics aspect (search the answer of problem, what has taken place poisonous substance in biological);
Toxicodynamics aspect (what has taken place biology under the effect of poisonous substance).
In the framework of toxicokinetics method, illustrate following character:
The physicochemical property of poisonous substance, it determines their behaviors in biological: molecular weight, the dissolubility in water and fat, ionizable ability;
Ability with albumen and some toxic receptor formation valence link;
To entering the explanation of biological approach, the distribution on molecule, cell and organ level;
Transform the biology in biochemical system;
From the excretory pattern of biology.
In the framework of toxicodynamics method, study following character:
The toxigenous effect of poisoning, relevant unusually with the physiologic function of different biochemical structures played the toxicity receptor, and this special symptom by the poisonous substance of discussion shows.
The effect of somatocyte development appears in the system of general biology, its adaptation response to chemical wound (stimulatory function of hypophysis-adrenal system, the shock reaction that blood circulation is concentrated etc.).
In this case, should consider, always take place based on the physiology system that determines as the poisoning of any kind of chemical disease, but with its active result's difference difference, this has obtained its unsuitable pathogenic character.
In the pathogenesis of poisoning, the principal element of following selection is arranged:
1. concentration coefficient, be the molecular concentration of toxicant in the biological media of biology (normally, μ g/ml), it is to instruct sexual factor, because it is relevant with the appearance of clinical symptoms under the toxic concentration of poisonous substance in the blood, and further develops up to potential deadly result relevant under lethasl concentration value (CL) with it.
2. the holdup time of time factor-determine poisonous substance toxicity dose in biological, the speed that it enters and discharges.This factor shows the relation between poisonous substance action time and its toxic action.Determine the kinetics of concentration and time factor, can distinguish the toxigenicity stage and the somatocyte development stage of poisoning, and absorb and the elimination time at the poisonous substance of toxigenicity in the stage.
3. space factor-the determine approach that enters, discharge, and the space of distribution of toxicant, its blood with supply organ and tissue aspect a lot of is relevant.
4. age factor-be reflected at life is hit the degree of different age specificitys biological sensitivity to poisonous substance in the stage, its from the childhood period change significantly to high age, the opposing to toxic action weakens 10 times and more at that time.
5. treatment factor is determined the reaction of biology to the antidotal therapy of enforcement, and this can produce several times of increases of the concentration threshold of the main poisoning symptom of development, and fully shortens the time in toxigenicity stage.
The pathogenesis that research is poisoned is based on following viewpoint: the toxicity receptor is as poisonous substance identification and the ad-hoc location that acts on.
In order to realize biological action, any chemical substance is considered to have at least 2 kinds of specific features: with the affinity and the inherent physical and chemical activity of receptor.
Term " affinity " is understood that the degree of material and acceptor interaction, and this degree is weighed by the tolerance that the speed of dissociating with " material-receptor " complex is inversely proportional to.
The toxic degree of material can be combined and be adjusted the molecule minimum number definition of phase place with important target cell by it.The important herein number that makes deleterious receptor of being not only, and be its importance degree to the vital activity of whole biology.Also importantly form speed, its stability of " poisonous substance-receptor " complex and reverse dissociated ability, it can become than receptor by the more significant factor of the saturated degree of poisonous substance.
Toxic action needn't have strict selectivity, its pair cell generation on the whole.This principle is implemented on a lot of poisonous substances, and wherein common characteristic is that they are not electrolyte.All effects represented in term " non-electrolysis ", and it is directly defined by physicochemical property, for example infusive or make us habit-forming material, and it is the feature of poisonous substance described herein (alcohols).
The most representative feature of the material in the group that this paper considers is the specific film-toxicity-effect that exists film-toxin to cause.The latter's feature is activity of phospholipase to be proved disintegrating of basic liquid-crystal film structure and the result of break (and the cell forfeiture further takes place).
Find that in a lot of research achievements under the poisoning that alkanol and pure succedaneum cause, the direct mechanism of himself film-toxicity-effect or its metabolite is the peroxidating (POL) of lipid.The process of lipid peroxidation cell inner membrance has obtained the feature with the chain reaction of a large amount of cell forfeitures, and described cell forfeiture is the result who exhausts biological natural anti-oxidation system (AOS).
Detoxifcation (detoxifcation), one of the most remarkable mechanism as chemical resistance, it is biochemical and complex that the biophysics reacts in biological, it relates to chemical homeostasis and keeps, this is to guarantee that by some system cooperating performance functions of natural detoxifcation (neutralization of the toxicant of exogenous origin and endogenous origin) described system comprises:
Haematogenic immunity system (blood protein and hemocyte);
Liver detoxification system (MC, as to relate to P-450 enzyme and non-MC) at the composition of the specific enzyme that is used for transforming biology hydrophobic and hydrophilic substance.For the poisonous substance of this paper, this fermentoid is an alcoholdehydrogenase regulating liver-QI acetal dehydrogenase;
Excretory organ system (gastrointestinal tract, kidney, lung and skin).
Be no more than under the situation of certain threshold level at the exogenous and haemoconcentration endogenous cytotoxic material, the normal function of natural antidotal General System rationally reliably will be exogenous with the endogenous cytotoxic material from bioscrubbing.In addition, there is the accumulation of toxicant molecule, and the poison mode development is arranged at the toxicity receptor.The degree of its performance depends on the combination of different factors, under a large amount of situations, it can partly or all sidedly the accumulation with metabolite be relevant, and this is proved has than the remarkable bigger toxicity of natural materials (methanol, ethylene glycol etc.), transforms its biology and carries out along route of intoxication.On the other hand, toxicant to the action intensity of biology in premorbid unusual following increase, describedly be present in main detoxification system part unusually, especially the function (situation toxicity) of liver, kidney and immunity, and for old and old patient, toxicant also increases the action intensity of biology.In this case, develop toxic action being lower than under the toxin blood concentration of threshold value.
Under all surpass the situation of toxicity load threshold level, need be with the system of the natural function of detoxification of performance that mode stimulates or additional maintenance is used to clean quickened.
Antidotal toxicodynamics effect shows that with certain clinical symptoms its content depends on the clinical stages and the selective toxicity of poisonous substance.
In the toxigenicity stage (phase) of acute poisoning, this stage carries out when there is the toxic concentration of poisonous substance in blood, what at first arouse attention is the specific symptoms of disease, and it depends on the pattern and the function of clear and definite toxicity receptor, toxicant and described acceptor interaction.
In the chronic poisoning different, after long-term general physical obstacle, significantly showed specific toxigenicity symptom afterwards with acute poisoning.
The therapeutic treatment of poisoning comprises the specific treatment measure of enforcement of combination, and it is realized in 2 main directions:
1) termination is any further enters, and implement to quicken to discharge toxicant (initiatively antidotal output intent) from biology, and, if possible, by using specific (having Detoxication) pharmacotherapy, implement the quick neutralization of poisonous substance, described treatment reduces the toxicity (toxicokinetics correction) of poisonous substance;
2) pharmacology protects and keeps biological described function, and described biological know-how will experience the damage that toxicant causes, i.e. the symptomatic treatment and the help (toxicodynamics correction) of recovering.
Under some pattern of the poisoning with obvious selective toxicity, the application of special antidote (counterpoison) can influence toxicant or its receptor immediately, reduces its toxicity.
The detoxification of somatocyte development in the stage also relates to the endogenetic toxicosis (endotoxicosis) that elimination develops under the situation of organa parenchymatosum's damage (for example under the situation of acute kidney or hepatic insufficiency).
In the toxic action of alkanol, 2 kinds of compositions are emphasized to specific and nonspecific.
Nonspecific action is relevant with the characteristic of physicochemical property, and is regulated by so-called non-electrolyte effect (being the effect of overall molecule material by the mechanism of existence).The non-electrolyte effect shows as the film fluidization, as a result of, shows its abnormal function.Described alkane alcohols-inherent osmotically active causes the liquid displacement between Different Organs and tissue, the inhibition of platelet aggregation, has developed ARR myocardium to adrenergic sensitization.
The feature of the clinical manifestation that non-electrolyte is poisoned (it relates to described alcohols and its metabolite) is that similar state, the cardiac contractility ability that is in poisoning (or dizzy) weakens and the endocellular metabolism obstacle.
What research was maximum under laboratory and clinical condition is the pattern of ethylism.A series of its brains, liver, the heart and kidney toxic action have been determined, to synapse (synaptotropic) with to the mechanism of the toxic action of film (membranotropic) character.Hereinafter these mechanism will be described briefly, to such an extent as on their basis,, characterize the toxic action of the poisonous substance of this paper consideration after a while by analogy.
Ethanol is by the oxide reductase, promptly by (latter is specific NAD-dependent enzyme) at the hepatocyte cytosol, alcoholdehydrogenase (ADG) in the MEOS of liver (MSES), and by catalase, oxidase and peroxidase oxidation in tissue.Alcoholic acid oxidation causes forming aldehyde, i.e. acetaldehyde.Acetaldehyde is contained liver enzyme (being aldehyde dehydrogenase (the AcDH)) oxidation of FAD, and to form acetic acid (acetic acid), it further generates CO gradually by metabolism
2And H
2O.
To the realization of central nervous system's (CNS) toxic effect of ethyl alcohol unusual adjusting, describedly cause by this effect unusually, and in film-action effect, show by functional medium system.Its specific influence to gamma aminobutyric acid (GABA), glutamatergic system changes the permeability and the affinity of film ion channel, changes the function of neurotransmitter system thus.
Transform in the ethanol in biology, produce the recovery form of a large amount of acetaldehyde, acetate and ADG-NADH enzyme.Finally, it is a series of biochemical unusual reasons that caused by alcoholic acid introducing.Under the situation of ethylism, tricarboxylic acid cycle is blocked by acetaldehyde, no longer can utilize acetyl group-coenzyme A, and it causes forming ketone, and changes the synthetic process of fatty acid.According to this basis, the development metabolic acidosis.As everyone knows, a large amount of acetaldehyde cause the respiratory chain mitochondrial function unusual, make its energy function disorder thus.Based on this, form the myocardium dysfunction.
According to our viewpoint, must be pointed out that ADG can catalytic alcohol be converted into the redox reaction of aldehyde, and be not only applicable to ethanol, also be applicable to a lot of other alcohols, at least above it is mentioned those alcohol of so-called intoxicating phenomenon.Another supports that the argument of this reason is the following fact: in the poisoning that many alcohols cause, ethanol is used as special antidote, and its effect is by its competitive inhibition alcoholdehydrogenase and prevent that then the ability of the oxidation of these poisonous substances from explaining.What can classify as this class alcohol is, methanol, carbon chain lengths have aliphatic alcohols, the dihydroxylic alcohols of 5 atoms at the most, with and ether (glycol monoether) with alcohol groups, i.e. those pure and mild its derivants, it is according to typical poisonous substance of the present invention.
Therefore, by those alcoholism that cause (described alcohol is oxidized to its aldehyde by ADG) of described alcohols, observe the quite similar pattern of the toxic effect of described poisonous substance at least.
The cytoplasmic acidosis of the imbalance of cell membrane physicochemical property, alcohol membrane damage that converted product causes biology, growth, imbalance, cell protein and lipid self-dissolving activation of a procedure, abnormalities of sugar/lipid metabolism, the peroxide activation of a procedure of energy process are the characteristic features of specific alcohols effect.On this basis, necrosis and underfed (steatosis) that has developed in the cell of most important organ changes.
Toxic effect of methanol is generally regulated by its metabolite (being formaldehyde and formic acid).Formaldehyde itself is the strongest poisonous substance, and its metabolite also can be disruptive oxidation and the chain of phosphorylation, causes metabolic acidosis, changes the normal processes of a large amount of main biochemical processes.
In ethylene glycol is poisoned, glyoxalic acid (after the enzymatic conversion first time that relates to ADG) its converted product biology appears in succession, for example; This is single aldehyde, glycolaldehyde (glycole aldehyde) (after the enzymatic conversion second time that relates to ADG), and this is a dialdehyde, is oxalates afterwards, hydroxyacetic acid.Those serial all substances are destroyed the function of tricarboxylic acid cycle enzyme.The aldehydes that occurs is deleterious, and accumulation in biological for a long time, and aldehydes can destroy important biological function in the mode by system.
Ethylene glycol mono-ether experiences approximately uniform metabolic pathway, because its alcohol groups of ADG " attack ", owing to this reason, monoether is converted into relevant aldehyde.According to this point, form glycolic (oxyacetic acid) from ethylene glycol mono-ether, it the cellular metabolism acidosis occurs also causing.Under combined effect, these chemical compounds are regulated the appearance of hypokalemia and hypocalcemia, and homergy and the adenosine triphosphate (ATP) of destroying glucose, lactic acid are synthetic, and destroy the function of a large amount of enzyme systems.
At cellular level, above-described process is thought to develop a series of pathogenic unusual beginnings: homeostasis obstacle (metabolic acidosis, water-electrolyte imbalance, blood coagulation change and other obstacle), and form the secondary syndrome: the inaccessible adnormal respiration of consciousness depression, maincenter and suction, acute cardiac vascular insufficiency, organa parenchymatosum's damage etc.On the basis of the above, developed the process that much has deadly risk.These processes comprise following situation:
Acute respiratory distress (ventilation and substantial function are incomplete);
Circulate poverty-stricken (former with other) because the basis with cardiac contractility ability decline, toxicity cardiomyopathy, hypovolemic (oligemic) shock;
Cerebral disorders;
Organa parenchymatosum's's (liver, kidney, cardiac muscle) damage and dysfunction.
In the clinical module that AS-poisons, select following characteristic symptom:
The toxicity encephalopathy;
Adnormal respiration;
Blood circulation is unusual;
The toxicity hepatopathy;
The toxicity nephropathy;
Homeostasis obstacle (water-electrolyte balance, Acid-Base balance);
Stomach-intestinal obstacle.
These syndromes are described in detail in the following list of references: [source 1:Luzhnikov E.A., people such as Ostapenko Yu.N..“Emergency status under acute poisonings”M.,2001]。Up to now, in the poisoning that methanol according to the present invention, ethylene glycol and its poisonous substance cause, ethanol has been used as special antidote, and uses [source 1, the 155-156 page or leaf] as the competitive inhibitor of alcoholdehydrogenase through intestinal and/or intravenous.This Therapeutic Method has a large amount of shortcomings, because ethanol energy inhibitory enzyme system itself and organa parenchymatosum's function, it faces following demand: continue comprehensive monitoring patient's states, the natural detoxification system ability of patient, premorbid factor, poisoning seriousness, poisoning stage etc.
The objective of the invention is to make effective agent to enter circulation, development with prevention or blocking-up pathological process, or reduce its speed, described pathological process by single and repeatedly, what particularly prolong uses alcopop to cause with systematicness, and described beverage also contains the poisonous substance beyond the ethanol itself.These poisonous substances are present in the beverage as the natural mixture that comes across in the alcohol fermentation preparation process.The toxicity mixture is present in the beverage may also exist some other reasons.In addition, the present invention concentrates on effective ways and medicament is introduced the toxicology practice, prevents and Drug therapy with the poisoning that alcohols and its derivant are caused.
By being designed for medicament through intestinal or parenteral, solved this specified task, described medicament is represented the ortho position dithioglycol of at least a general formula (1), and if desired, together prepares with the carrier of pharmaceutically acceptable carrier or food.Described ortho position dithioglycol is meant the material of following general formula
R
1(CH
2)
nCH(SH)CH(SH)(CH
2)
mR
2 (1)
R wherein
1And R
2Can be independently selected from following groups: (H), (OM '), (COOM '), (SO
3M '), (O-CH
2-SO
3M '), (PO
3M
2'), (PO
2SM
2'), (PO
3M "), (PO
2SM "), symbol M wherein ' expression hydrogen or alkali metal ion, symbol M " the expression alkaline-earth metal ions, wherein m and n are independently selected from 0 to 5 integer.The chemical compound of general formula (1) is that prior art is known.It is described and route of synthesis is listed in, and for example the ChemicalEncyclopedia[source 2: " Chemical Encyclopedia ", M.:SovietEncyclopedia Publishing House, 1990, v.2, the 91-92 page or leaf].Described ortho position dithioglycol (VD) is meant following compounds particularly:
1. dithioglycol (dimercaprol, dimercaptopropanol, BAL, Dimercaprol, Dimercaprol [BAL]), it has following formula:
2.2, the 3-Sodium Dimercapto Sulfonate (" sodium dimercaptopropanesulfonate (Unithiol) ", DMPS), it has following formula:
3.2, the 3-dimercaptosuccinic acid (" dimercaptosuccinic acid ", DMSA), it has following formula:
(4.2-2,3-dimercapto propoxyl group) ethane sulfonic acid sodium (" Oxathiol "), it has following formula:
Ortho position ethylene dithiol alcohols is used as the active medicine of radioprotective, when heavy metal and its chemical compound cause poisoning, when particularly causing poisoning by arsenic, lead, hydrargyrum, also is used as antidote [source 3:Mashkovsky M.D. " Medications ", M., 1993].These are the low molecular compounds with 2 ortho position sulfydryls, because described sulfydryl, they show good capturing ability to heavy metal (comprising radionuclide).
The purposes of these materials is known in the technical field of toxicology practice.When arsenic, bismuth, hydrargyrum, antimony or zinc cause poisoning, dithioglycol (BAL) and 2,3-Sodium Dimercapto Sulfonate (DMPS) is as antidote [source 4:Shiebak V.M., people's " TheFundamentals of Clinical and Analytical Toxicology " (list of references handbook) such as Panchenko L.F., by Tomilin V.V. //professor Moscow edits, 2002, the 46 pages].2,3-Sodium Dimercapto Sulfonate (DMPS), 2,3-dimercaptosuccinic acid (DMSA) and other ortho position dithioglycol (VD) are as the antidote at so-called destructive poisonous substance, and described destructive poisonous substance comprises heavy metallic salt, arsenic and its chemical compound, and the chemical compound of some phosphorus and chlorine.Also known, under the situation that mental disorder alcoholism (alcoholicum), acute alcoholism, narcotic are poisoned, with the Comprehensive Treatment of other antidote combination in, use DMPS (2, the 3-Sodium Dimercapto Sulfonate) [source 3].Known in antidotal therapy as one of its stage, use 2, the 3-Sodium Dimercapto Sulfonate, alleviate fast withdrawal symptom [source 5: " Alcoholism ", by G.V.Morozov, M. edits, Medicina Publishing House, 1985, the 314-321 pages or leaves].Also known in process by the dependence disease that uses ethanol or other psychoactive drug substance to cause, use the development (patent RU 2229291) of VD blocking-up or minimizing pathological process.
The invention provides the purposes that known substance is used for new purpose.
Summary of the invention
The applicant finds first, under known index listed above, behind enteral administration, ortho position ethylene dithiol alcohols (VD) has shown beat all stronger effect, unexpectedly find in addition, after administration, especially behind the oral administration, the ortho position dithioglycol provides new effect, the development that it at first shows blocking-up and/or suppresses pathological process, described pathological process is to be contained alcoholic acid beverage (containing toxic mixture) and/or contained pure beverage (not only contain ethanol as alcohol, and contain pure succedaneum as alcohol) by use to cause.This is listed the character that the people expects discovery and is the basis below effect: ortho position ethylene dithiol alcohols (VD) material of proposition is in vivo in conjunction with the direct metabolite of methanol, ethylene glycol and other unary alcohol and polyalcohols.Because we find this interactional characteristic, this effect is shown very consumingly, and described characteristic is a basic feature of the present invention.
First feature is, the interactional product of VD and specific poisonous substance can not be in cracking under the physiological conditions, and promptly they have chemoresistance.In other words, this reaction is irreversibly carried out in vivo.
Second feature is that for the described pharmacotoxicological effect to biology of significant, basic demonstration, the material (VD) that the present invention is proposed enters liver (fast as far as possible and complete).In order to carry out this effect, fit closely approach be the intestinal administration or, if the latter is prevented from, and equal with it, this drug administration by injection is suitable, it makes specific material access door venous blood flow.Especially by infusion in infusion or other portal vein in the portal vein of VD or through the umbilicus infusion, obtained this effect.
The 3rd feature (additional feature) be, if this class poisonous substance as deutero-aldehyde of alcohol and the reaction of water solublity ortho position dithioglycol, product also becomes water misciblely then, obtains the ability that together is discharged from by kidney and urine.This is 3 atoms and more carbochain for length, is very important, because from propionic aldehyde, and the poorly water-soluble of these aldehydes, and it reduces with the chain length increase.Based on this behavior, medicament and method as this paper proposes except these are the medicament and method of antidote Drug therapy, have become effective antidotal active agents and method; They not only quicken poisonous substance and eliminate, and can carry out the drainage of poisonous substance by kidney.For the drainage of ketone, identical process is real.Relate to kidney in the poisonous substance discharge process influences the concentration coefficient of pathogenesis with having superiority.
The 4th feature also is additional feature, and be as follows: because its suitable physicochemical property, alcohols has easily overcome organizes the hematogenous barrier, and is distributed in organ and tissue very equably.Then, therein, alcohols experience biotransformation, the phase I is converted into aldehydes.Aldehydes is bigger than alcohols toxicity, has stronger reactivity.The end group of aldehydes and plasma protein and hemocyte, enzyme and the reaction of other key element change their function (immunity thus, hemostasis, breathing, CNS, cardiac muscle, energy function and much other function be affected).In other words, the toxicity receptor of aldehydes more significantly than alcohols.Different with alcohols, aldehydes is proved to be to be organized in the haematogenous obstacle obviously poorlyer etc. overcoming, and it causes their accumulation in those organs and tissue, pure metabolism beginning (being the phase I of pure oxidation) in described organ and tissue.Simultaneously, under the effect of liver enzyme-aldehyde dehydrogenase, formoxy-ization takes place.In view of mentioned above, in organ outside liver and the tissue, any further formoxy-ization is prevented from, and this has aggravated the exposure (time factor) and the toxic action of aldehydes.This problem itself shows in the people who belongs to yellow's ethnic group in acute especially mode, because they have the aldehyde dehydrogenase activity of the reduction that is predetermined in the heredity.Can find the new solution of this problem according to the application of medicament of the present invention and method.Significantly, make enter liver according to active substance of the present invention (VD) after, the combination of aldehyde takes place.This causes the changes in balance in " alcohol-aldehyde " reversible reaction.So according to Le Chatelier principle, system is by strengthening pure oxidation and reducing its concentration in liver subsequently, to its reaction.According to identical principle, this cause alcohol from other organ and tissue further flow out with and flow into liver, to recover concentration.Be held if be present in the VD of liver, then the amount of the new aldehyde that is obtained by the pure oxidation that flows into liver is by combination once more, and this circulation repeats to take place.Therefore, use material according to the present invention and reduced the toxicity load at all organs and tissue because these materials promote poisonous substances from extremely important organ with organize rapid drainage.According to the viewpoint of poisoning pathogenesis, coming into effect this class Drug therapy as quickly as possible is important thing.According to the present invention, enter the circulation defending party to the application described herein who realizes under the condition of liver at maintenance active substance (VD) and be called " biological alcohol-aldehyde detoxifcation circulation " (CAAD).Point out that also CAAD also realizes by preventative VD administration.Therefore, CAAD produces useful influence to the time factor and the space factor of poisoning pathogenesis.
Therefore, the applicant has found the new pharmacological activity of a class of ortho position ethylene dithiol alcohols, be that they can make biology from alcohols and the detoxifcation of its metabolite in vivo, known described alcohols and its metabolite are strong poisonous substances, for example methanol and formaldehyde, propanol, butanols and amylalcohol and aldehyde thereof, di-alcohols and its aldehyde and monoether, and binary aldehydes, and on this basis, in the poison, utilize them in these as special antidote (first basic feature).Second basic feature according to the purposes of this new purpose is the medication of ortho position dithioglycol, according to this method, must guarantee that it is fully final and enter liver fast, because initial in this organ just toxicant metabolism and its poisoning take place.In the case, best solution is through enteral administration, but when status of patient needs, pointed out with drug administration to portal venous flow or through the umbilicus administration with together carry out through enteral administration, or use drug administration replaced through enteral administration to portal venous flow or through the mode of umbilicus administration.Based on this, the applicant provides medicament and the method that is used to prevent the poisoning that caused by the poisonous substance that above describes in detail with Drug therapy.
The explanation of technical result
Below, characterize by group, list effect, it obtains by medicament and the method (being technical result) that is illustrated, at first, its use with the typical poisonous substance that contains in the alcoholic solution that is intended to family's use is relevant, or relevant with the abuse alcopop, described beverage also contains toxic mixture, and the use of the poisonous substance of considering with this paper is relevant.
The 1st group: the toxicokinetics correction treatment
The chemical bond poisonous substance;
Prevent poisonous substance and toxic receptors bind;
Quickening poisonous substance and/or its toxic metabolites drains from biology;
Quickening poisonous substance drains from its organ that occupies and tissue (brain, lung etc.);
Prevent the poisoning of natural poisonous substance;
Increase poisonous substance or its metabolite and according to the water-soluble of the product of the active substance of medicament of the present invention;
Reduce the alcohol toxicity that the existence by one or more poisonous substances in the pure succedaneum causes;
Improving poisonous substance drains;
Prevention or reduce toxic effect to the effect of respiratory chain mitochondrion.
The 2nd group: the toxicodynamics correction treatment
Recover organa parenchymatosum's function;
Recover the function of neurotransmitter system;
Recover the CNS function;
Recover the energy function of cell.
The 3rd group: prevention
Prevention may enter the appearance or the development of the acute or subacute poisoning that causes in the biological process by poisonous substance at it;
Prevention is being used the appearance of the inferior chronic or chronic poisoning that causes in the process that contains pure liquid or pure succedaneum repeatedly or regularly or is being reduced its speed of development, and described liquid contains the poisonous substance of inferior toxicity dosage;
The seriousness of the poisoning of minimizing under the situation that poisonous substance may be taken in;
Increase the toxic threshold level that concentrates;
Influence concentration coefficient to reduce the toxic concentration value;
Reduce amount of poisons in the brain to such an extent as to influence concentration coefficient;
Reduce poisonous substance and expose (time factor);
Reduce biological sensitivity to poisonous substance;
In the process of its premorbid damage, strengthen liver and kidney function of detoxification (reducing situation toxicity);
Reduce the risk of endotoxin shock appearance and the seriousness of development.
Because the applicant has found the new property of general formula (1) chemical compound, another aspect of the present invention be take at least a according to poisonous substance of the present invention after, use at least a ortho position dithioglycol as the pre-anti-poisoning generation or the medicament of development.This purpose is new, because it is not based on the antioxidant properties of known detoxifcation, these materials.Relate to that to use VD also be new as the purpose of the active agents of preparation medicine, described medicament is mixed with dosage form or non-dosage form, is used to prevent or poisoning that Drug therapy is caused by poisonous substance according to the present invention.This class medicine can be represented compositions, and also comprises other active component.For the form of preparation, they can be to be used to ingest or the liquid or solid medicine of parenteral.
The ortho position dithioglycol can stop the destructive process of biomembranous free radical, and specifically, they protect myelinic ozone layer to avoid damage, protection hepatocyte, blood vessel and brain structure.On the basis of the above behavior of the ortho position ethylene dithiol alcohols of explanation, its administration can be blocked or lower cardiac muscular tissue, pancreas, vascular system, CNS and other organs of biology and the damaging action of system.
Ortho position ethylene dithiol alcohols is relevant with the pharmacological effect of using poisonous substance to these and other effects of described process, allows the appearance of those effects, and described effect is enumerated above, and represents the technical result of claimed technical scheme.
According to the present invention, the toxic action of using poisonous substance shows as the organ of a lot of biologies and the influence of system, and promptly these toxic actions cause beginning simultaneously or activating a considerable amount of pathological processes.Under the situation of the character of considering ortho position ethylene dithiol alcohols mentioned above or behavior, can infer that the latter has wholesome effect to this class pathological process of entire quantity, but this influence can be shown or realize, although simultaneously, have performance in various degree.Its influence is at first depended on its residing stage to the performance degree of particular pathologies process.The generation of some process can be blocked by the preventive administration according to medicine of the present invention, and the pathological process that other have begun can be suppressed by using these medicines.To the performance of particular pathologies process influence, the toxic action of using as poisonous substance is regulated, and also depends on strategy, toxicity load and other factors of dosage according to medicament of the present invention, individual body and other characteristics, drug administration.
The applicant has been found that when the dosage forms for oral administration medicament, above the effect that has superiority on Shuo Ming the physiology is proved to be with strong especially degree.As if to enter some characteristic of the high-speed and described material of liver and liver enzyme interacting relevant with active substance for this phenomenon.This more inapparent effect also can be observed at topical and the inhalation-type drug administration by oral mucosa, nose.
Above Shuo Ming effect has been expanded the character of known up to now ortho position ethylene dithiol alcohols significantly.Their known detoxicating activities are used to reduce the acute situation of giving up, and promptly are used for the treatment of the people by the alcoholism influence.With 2, the 3-Sodium Dimercapto Sulfonate is treated mental disorder alcoholism to the patient, and described patient suffers from original (the 3rd) alcoholism of clinical stages, and the feature of described clinical stages is the appearance of serious spirituality obstacle.Known antioxidant activity has also replenished the new ability of ortho position ethylene dithiol alcohols well.The applicant has been found that ortho position ethylene dithiol alcohols can alleviate the be still drank after a night seriousness of (or alcohol withdrawal syndrome) situation of domestic levels before, and its hint is used alcoholic acid harmful result, and it appears at second day that uses behind the ethanol.This effect causes (patent RU 2157647C1 number, 2000) to the activity of acetaldehyde in vivo by VD.At present, based on newfound effect in test, it can be asserted that the effect of ortho position ethylene dithiol alcohols (as active substance) shows by their administration, it takes place discretely with the fact of using AS, for example by several weeks (Drug therapy process) or a couple of days before taking in AS, or a few hours during in preventive administration show.At other poisonous substances identical phenomenon is arranged.Importantly, notice that the applicant has determined the effect of the pathogenetic common contact of the poisoning that ortho position ethylene dithiol alcohols causes the metabolite by alcohols and its Different Origin.
Therefore, have reason very much the known properties of ortho position ethylene dithiol alcohols and the synergism of the character that above illustrates are reached a conclusion, it allows for new purpose, recommends its application.
The medicament forms of the medicament that proposes can comprise and being suitable for through enteral administration, particularly oral administration, by probe administration, nose administration, part (comprising) administration by oral mucosa, or by suction or the form by drug administration by injection through cheek and Sublingual.The medicament that proposes can have the solution form that is used for drug administration by injection.In this case, mix with suitable liquid component by the active substance that will propose, and carry out its administration down, thereby prepare infusion solution the auxiliary of related preparation equipment according to the present invention.Pharmaceutical preparation can be represented compositions, and the form of the administration unit that can disperse easily provides, any method preparation of can the pharmaceutics field knowing.All these method of pharmacy comprise active substance and liquid-carrier or broken solid carrier or their both (if desired) the blended steps of fine powder, and step subsequently is, product are molded into the shape of expectation, if this needs.
The pharmaceutical preparation that is suitable for oral administration can show as the form of discrete unit, for example tablet, capsule, cachet, and they contain the active component of preliminary recipe quantity separately; Or show as powder or particulate form; Or show as the form of solution, suspension or emulsion.Active component can also show as the form of bolus or paste, or exists with its pure form, does not promptly contain carrier.The tablet and the capsule that are used for oral administration except additional physiology goes up activated composition, also can contain common received additive, for example adhesive, filler, lubricity material, fluffer (fluffer), wettability material.Push or pressing mold with described form by optional and one or more additional compositions, can prepare tablet.In suitable machine, can be the active component of free-flowing form by extruding, for example, prepare compressed tablets with the powder or the granule of optional approach and adhesive, lubricity material, inert diluent, lubricant, surfactant or dispersant.On suitable machine, by the mixture (by the moistening mixture of inert liquid diluent) of mould-casting powder compound, the preparation molded tablet.Can use according to method well known in the art shell coated tablet.Liquid oral medicine can be the form of aqueous for example or oily suspensions, solution, emulsion, syrup or elixir, maybe can show as the form of water before use or the blended dryed product of other appropriate solvent.These liquid preparations except the additional physiologically active composition of introducing, also can contain common received additive, for example suspending agent, non-aqueous solvent (it can comprise edible oil), flavoring additive, aromatic, coloring agent or antiseptic.Can choose the form that preparation is above enumerated wantonly, with provide the active substance that wherein contains slowly or the drainage of control.
Be intended to by the oral mucosa topical, for example comprise and containing at its correctives substrate (carbohydrate for example by form through cheek or sublingual administration approach, for example sucrose, arabic gum or Tragacanth) in the lozenge of active component, and the pastille that in substrate, contains active component, described substrate is for example gelatin, glycerol, carbohydrate, arabic gum etc.For the intranasal administration of active substance of explanation above, operable form is that for example aerosol maybe can become the powder or the drop of powder.These drops can use or non-aqueous substrate make, it also contains one or more dispersants, solubilizing agent or suspending agent.Liquid aersol is convenient to being packaged to be from pressurization.For inhalation, chemical compound according to the present invention be convenient to from the insufflator that is used to prepare aerosol spray, suction-type pressurized package or other easily device obtain.Packing under pressure can contain suitable propellant, for example dichlorodifluoromethane, Arcton 11, carbon dioxide or other suitable gas.For the aerocolloidal situation under pressure, provide spraying by the valve that uses the amount of supplying metering, thereby determine dosage unit.
Selectively, for giving can use the form of dry powder powder mixture according to material of the present invention by sucking or being blown into, the powder mixture of active substance and relevant Powdered substrate for example, described substrate is for example lactose, starch, Talcum.The form that powdered composition can show as single dose exists, and for example capsule, cartridge case, gelatin or cohesiveness plaster packing can be introduced described powder by inhaler or insufflator from above-mentioned form.
If desired, use above-described form, it is suitable for providing the lasting release of active component.
Also can contain one or more other active component according to drug agents of the present invention, its interpolation, as principle, be used to strengthen the effect of the material that proposes by the present invention, with and can be used to the composition that obtains to add and according to the synergism of chemical compound of the present invention.The active component that adds can be to be selected from following composition: vitamin, previtamin, vitamin derivative, organic acid, organic acid derivatives, lipid, the last activated peptide of physiology, aminoacid, amino acid derivativges, enzyme, enzyme derivative, enzyme precursor, coenzyme, coenzyme derivant, coenzyme precursors, carbohydrate, mineral, metal ion source, albumen and its mixture.For example, add aminoacid and have superiority, it is a neurotransmitter, for example glycine, γ-An Jidingsuan (GABA).Add metal ion source and have superiority because by methanol, ethylene glycol and much the poisoning that causes of other poisonous substances destroy water-electrolyte balance, cause hypocalcemia, cause that thus muscle rigidity shrinks.In this case, add divalent metal ion source and also have superiority, because some in them, for example magnesium, calcium, manganese play a significant role in enzyme catalysis, and it constitutes the part that coenzymatic composite divides.The shortage of calcium (as the regulator of a lot of processes), as noted above, with and metabolism toxicity suppress to quicken the development of a lot of pathological processes.As the additive that has superiority in medicament composition according to the present invention also can be the source of lipid; phospholipid particularly; for example lecithin, glycolipid; other liver protection things; vitamin particularly, for example alpha-tocopherol, its precursor, its derivant, the last activated peptide of physiology; neuropeptide for example, and much other physiologys known in the art go up activated material.
Be appreciated that the composition of partly enumerating except above, can comprise other compositions, medicament according to medicament of the present invention, it is considered to conventional in this application, and is used to the form of the special medicament of discussing of this paper.For example, the medicine that is used for oral administration can contain correctives or structure-formation agent.Especially, what relate to poisoning prevention significantly can be mixed with medicament forms or non-medicament forms according to medicament of the present invention, for example is mixed with food product form, particularly beverage.
The preferred form that contains fractionated dose is the form of active substance according to the present invention that contains effective dose, and is as mentioned below, or contains the form of the described dosage of suitable part.
In order to reach recommended target, according to the present invention, above Shuo Ming the medicament that contains the effective dose active component can be by oral or different approach easily with dosage 0.1 to 250mg/kg (every kg of patient body weight) introducing every day.General adult's the common scope of dosage level every day be about 5mg to about 10g, normally at littler about 50mg extremely in the scope of about 2g, most preferred scope is from 100 to 1000mg every days.Tablet or other forms of the medicament that provides with the form of discrete unit are used for it is convenient, can contain under this dosage effectively amount, or a plurality of amount, for example contain 50mg to 1000mg, are generally about unit of 200 to 500mg.
Introduce according to pharmacy optimization per os of the present invention, adopt accurate dosage and respectively, described dosages of substance should give according to application specifications or expert's recommendation.But the actual dosage that uses depends on several factors, and it comprises sex, age, body weight, risk factor, situation that the poisonous substance picked-up causes, individual body and spiritual neurological characteristic etc.When the time of determining to use medicament and persistent period (speed), should note the factor of identical type.Can recommend the form administration of medicament with process, when it can be prescribed before may using alcopop, it relates to the risk or the harm of poisoning, and/or poisonous substance enters other biological possible approach (breathing, suck), or in using this class beverage (or make poisonous substance enter biology by other modes) back certain time interval, or before using and afterwards, or contain in the different combination of beverage of Toxic in use.According to this point, adjusting gives the moment of medicament and uses above cited can partly the making up each other with other possible choices of using the time relationship between the moment of alcopop or AS or other poisonous substances.
For parenteral, use the infusion agent of special preparation usually.For its preparation, active substance according to the present invention is mixed with appropriate solvent.Can use the water of special adjusting as this solvent.
Hereinafter the embodiment of Xian Shiing has illustrated essence of the present invention, but the scope of invention of requirement for restriction protection not.
Embodiment 1. sodium dimercaptopropanesulfonate tablets
Mix 25g sodium dimercaptopropanesulfonate (powdered substance), 5g lactose, 10g aerosil, 30g starch, 5g sodium starch glycolate, 5g magnesium stearate, 1g calcium pantothenate, 7g folic acid, moistening gained mixture, fully stir, homogenize and tabletting obtain the 0.5g tablet.
Tablet formulation
The instant capsule that embodiment 2. usefulness are particles filled, it comprises:
Composition | mg |
Dimercaptopropanol, BAL | 50 |
Dimercaptosuccinic acid | 50 |
Sodium dimercaptopropanesulfonate | 100 |
Succinic acid | 100 |
Calcium citrate | 100 |
Lecithin | 50 |
Magnesium oxide | 50 |
Pyridoxine hydrochloride | 20 |
Make granule according to known technology in pharmacology's technology.
The application that is used for above-described purpose has adopted laboratory animal to detect.The applicant initiatively studies the detoxifcation behavior (using sodium dimercaptopropanesulfonate as an example) of ortho position ethylene dithiol alcohols.
It is that the male rat of the Wistar-100 strain of 150-250g carries out that the experimental section of 3. work of embodiment adopts initial body weight.These animals are raised under the artificial lighting condition of (12 hours every days), and free contact standard mixed feed and water.
These animals are divided into 4 groups (3 experimental grouies, 1 matched group).Each group all detected biochemical physiochemical indice before experimentizing: triglyceride, liver enzyme: alanine aminotransferase of peroxide procedural strength (AlAT) or serum glutamic pyruvic transminase (SGPT) and aspartate aminotransferase (AsAT) index-TBA-positive products (detecting) with thiobarbituric acid, and the index of biological antioxidant system: uric acid, vitamin E, A; The SH group.
In first experimental group (EG1), under the situation that does not have prevention also not have to handle, animal is poisoned; In one hour, these animals are used placebo with the form of gelatine capsule.In second experimental group (EG2), in poisoning preceding 1 hour, with the amount of the sodium dimercaptopropanesulfonate in the gelatine capsule with the every kg body weight of 150mg, per os gave these animals.In the 3rd experimental group (EG3), after poisoning in half an hour, described animal is used the sodium dimercaptopropanesulfonate in the capsule of same amount.
For obtaining the acute poisoning that methanol causes, give rat with 1ml dosage per os and single with methanol aqueous solution.
The zoopery result shows, lipid peroxidation end-product in the blood plasma of poisoning rat (EG1), and (EG2 EG3) has clear and definite difference to the concentration numerical value of TBA-positive compound aspect increase than the sodium dimercaptopropanesulfonate administration group of the same period.The content of main endogenous antioxidant-vitamin E of EG1 rat, A, SH group obviously reduces.The relatively demonstration of the amplitude chart of all three treated animals, the violent reduction of Vitamin E levels appears in the animal of only accepting methanol and placebo.The animal of accepting sodium dimercaptopropanesulfonate and methanol simultaneously maintains the meansigma methods of vitamin E on the level of values of control groups.At other endogenous antioxidants: observe identical pattern in the variation of vitamin A and SH group.
Also proved, the enzyme labelling thing to damaging hepatocellular activity (AlAT, AsAT) in EG1 apparently higher than the group of accepting sodium dimercaptopropanesulfonate.To the relatively demonstration of the biochemical indicator of EG2 and EG3, accept the EG2 treated animal of sodium dimercaptopropanesulfonate, from the survival significantly better of poisoning as preventive measure.This also shows when observing animal, its behavior and reaction.
Check that in back 12 days of poisoning the result according to the animal tissue of ethics biology criterion sacrificed by decapitation shows, maximum damage takes place in EG1 animal tissue.In lung tissue, be clear that focus infiltration, alveolar membranes thicken and the edema due to disorder of QI position.In cardiac muscle, observe the strong hyperemia of endocardium blood vessel, the fragmentation of individual fibers.In liver, observe hepatocellular granularly and drip the malnutrition of shape, the strong hyperemia of central vein, there is beam (beam) structure of two garland cellss, diffusion.Kidney is changed influences minimum, observes the hyperemia of some blood vessels and the moderate change in the brain layer.
For the EG3 animal, in tissue, observe similar variation, it is more not obvious that these change performance: liver is more complete, has kept girder construction; Malnutrition in the myocardial cell changes more not obvious; There is not the edema due to disorder of QI position in the lung.It is minimum as changing in the tissue of the EG2 animal of preventive measure to accept sodium dimercaptopropanesulfonate.In liver, under the situation of central vein hyperemia, hepatocyte is more complete, although also observe granular malnutrition.In lung, there is the focus infiltration.In cardiac muscular tissue, exist the myocyte to consume.
The result that research is learned by this test organization allows effect is drawn as drawing a conclusion: the acute poisoning that the ortho position dithiols causes methanol has shown therapeutic and preventative character.
It is the male rat of the Wistar-100 strain of 150-250g that the experimental section of 4. researchs of embodiment adopts initial body weight.These animals are raised under the artificial lighting condition of (12 hours every days), and free contact standard mixed feed and water.
These animals are divided into 4 groups (3 experimental grouies, 1 matched group).Each group all detected biochemical physiochemical indice before beginning experiment: triglyceride, liver enzyme: the alanine aminotransferase of peroxide procedural strength (AlAT), serum glutamic pyruvic transminase (SGPT) and aspartate aminotransferase (AsAT) index-TBA-positive products (detecting) with thiobarbituric acid, alkali phosphatase, and the index of biological antioxidant system: uric acid, vitamin E, A; The SH group.
In first experimental group (EG1), under the situation that does not have prevention also not have to handle, animal is poisoned; In one hour, these animals are used placebo with the gelatine capsule form.In second experimental group (EG2), in poisoning preceding 1 hour, with the amount of the sodium dimercaptopropanesulfonate in the gelatine capsule with the every kg body weight of 150mg, per os gave these animals.In the 3rd experimental group (EG3), in back 30 minutes of poisoning, also these animals are used sodium dimercaptopropanesulfonate in the capsule.
For obtaining the acute poisoning that ethylene glycol causes, give rat with 1ml dosage per os and single with glycol water.
The zoopery result shows, lipid peroxidation end-product in the blood plasma of poisoning rat (EG1), and (EG2 EG3) has clear and definite difference to the concentration numerical value of TBA-positive compound aspect increase than the sodium dimercaptopropanesulfonate administration group of the same period.The content of main endogenous antioxidant-vitamin E of EG1 rat, A, SH group obviously reduces.The relatively demonstration of the amplitude chart of all three treated animals, the violent reduction of Vitamin E levels appears in the animal of only accepting ethylene glycol and placebo.The animal of accepting sodium dimercaptopropanesulfonate and ethylene glycol simultaneously maintains the meansigma methods of vitamin E on the numerical value level of matched group.At other endogenous antioxidants: also observe identical pattern in the variation of vitamin A and SH group.The alkaline phosphatase enzyme level of EG1 animal raises.
Also proved, the enzyme labelling thing to damaging hepatocellular activity (AlAT, AsAT) in EG1 apparently higher than the group of accepting sodium dimercaptopropanesulfonate.To the relatively demonstration of the biochemical indicator of EG2 and EG3, accept the EG2 animal of sodium dimercaptopropanesulfonate, from the survival significantly better of poisoning as preventive measure.The described index of control animals is proved to be stable.
Check that in back 12 days of poisoning the result according to the animal tissue of ethics biology criterion sacrificed by decapitation shows, exists maximum damage in EG1 animal tissue.In lung tissue, be clear that focus infiltration, alveolar membranes thicken and isolating edema due to disorder of QI position.In cardiac muscle, strong hyperemia and the dystrophic of observing blood vessel change.In liver, observe hepatocellular granular and drip the malnutrition of shape, the strong hyperemia of central vein, the girder construction of non-a large amount of diffusions.In kidney, small intestinal and pancreas, do not observe visible variation.
For the EG3 animal, in tissue, to observe similar variation, but compare with the EG1 group, it is more not obvious that these change performance: liver keeps more completely, has kept girder construction; Malnutrition in the myocardial cell changes more not obvious; Although observe individual myocyte's hypertrophy, there is not the edema due to disorder of QI position in the lung, although alveolar membranes thickens yet.It is minimum as changing in the tissue of the EG2 animal of preventive measure to accept sodium dimercaptopropanesulfonate.In liver, under the strong congested situation of central vein, hepatocyte keeps more completely, although also observe granular malnutrition.In lung, there is the focus infiltration.In cardiac muscular tissue, exist the myocyte to consume.
This test allows effect is drawn as drawing a conclusion to the result of Histological research of animal tissue: the acute poisoning that the ortho position dithiols causes ethylene glycol has shown therapeutic and preventative character.
Claims (25)
1. the ortho position dithioglycol of at least a general formula (1) is used for the treatment of the purposes of the poisoning that is caused by at least a toxic component that contains pure liquid and/or pure succedaneum,
R
1(CH
2)
nCH(SH)CH(SH)(CH
2)
mR
2(1)
R wherein
1And R
2Can be independently selected from following groups: (H), (OM '), (COOM '), (SO
3M '), (O-CH
2-SO
3M '), (PO
3M
2'), (PO
2SM
2'), (PO
3M "), (PO
2SM "), symbol M wherein ' expression hydrogen or alkali metal ion, symbol M " the expression alkaline-earth metal ions, wherein m and n are independently selected from 0 to 5 integer.
2. according to the purposes of claim 1, it is characterized in that in intestinal and/or portal vein infusion or give the ortho position dithioglycol of at least a general formula (1) through the umbilicus infusion.
3. according to the purposes of claim 1, it is characterized in that when treating the poisoning that is caused by at least a toxic component that contains pure liquid and/or pure succedaneum, the ortho position dithioglycol of at least a general formula (1) is as special antidote.
4. according to the purposes of claim 3, it is characterized in that in intestinal and/or portal vein infusion or give the ortho position dithioglycol of at least a general formula (1) through the umbilicus infusion.
5. according to claim 1,2,3 and 4 each purposes, it guarantees to obtain at least aly to proofread and correct relevant effect with the poisoning toxicodynamics, and it is selected from:
Recover organa parenchymatosum's function;
Recover the function of neurotransmitter system;
Recover central nervous system's (CNS) function;
Recover the energy function of cell;
And/or guarantee to obtain at least aly to proofread and correct relevant effect with the poisoning toxicokinetics, it is selected from:
The chemical bond poisonous substance;
Prevent poisonous substance and toxic acceptor interaction;
Quickening poisonous substance and/or its toxic metabolites drains from biology;
Quickening poisonous substance drains from its organ that occupies and tissue (brain, lung etc.);
Prevent the poisoning of natural poisonous substance;
Increase poisonous substance or its metabolite and according to the water-soluble of the product of the active substance of medicament of the present invention;
Reduce the alcohol toxicity that the existence by one or more poisonous substances in the pure succedaneum causes;
Improving poisonous substance drains;
The prevention or reduce bringing into play the toxic effect of mitochondrial respiratory chain effect.
6. the ortho position dithioglycol of at least a general formula (1) is used to prevent the purposes of the poisoning that at least a toxic component by liquid that contains alcohol and/or pure succedaneum causes.
7. according to the purposes of claim 6, it is characterized in that giving the ortho position dithioglycol of the general formula (1) of at least a claim 1 through intestinal.
8. according to the purposes of claim 6, it is characterized in that the special antidote of the poisoning that the ortho position dithioglycol of the general formula (1) of at least a claim 1 is caused by at least a toxic component of liquid that contains alcohol and/or pure succedaneum as prevention.
9. purposes according to Claim 8 is characterized in that giving through intestinal the ortho position dithioglycol of at least a general formula (1).
10. according to claim 6,7,8 and 9 each purposes, it guarantees to obtain the relevant effect of risk at least a and that poison and occur, and it is selected from:
Prevention may enter the appearance or the development of the acute or subacute poisoning that causes in the biological process by poisonous substance at it;
Prevention is being used the appearance of the inferior chronic or chronic poisoning that causes in the process that contains pure liquid or pure succedaneum repeatedly or regularly or is being reduced its speed of development, and described liquid contains the poisonous substance of inferior toxicity dosage;
Reduce the seriousness of the poisoning in the process that may use poisonous substance;
Increase the toxic threshold level that concentrates;
Influence concentration coefficient to reduce the toxicity that concentrates;
Reduce amount of poisons in the brain to such an extent as to influence concentration coefficient;
Reduce poisonous substance and expose (time factor);
Reduce biological sensitivity to poisonous substance;
In the process of its premorbid damage, strengthen liver and kidney function of detoxification (reducing situation toxicity);
Reduce the risk of endotoxin shock appearance and the seriousness of development.
11. the method for the poisoning that prevention is caused by the liquid that contains alcohol and/or at least a toxic component of pure succedaneum, it comprises the ortho position dithioglycol that gives at least a general formula (1) of claim 1 through intestinal.
12. the method for the poisoning that Drug therapy is caused by the liquid that contains alcohol and/or at least a toxic component of pure succedaneum, it comprises the ortho position dithioglycol that gives the general formula (1) of at least a claim 1 through intestinal.
13. the method for the poisoning that Drug therapy is caused by the liquid that contains alcohol and/or at least a toxic component of pure succedaneum, it comprises the ortho position dithioglycol that gives the general formula (1) of at least a claim 1 through intestinal and parenteral.
14. the method for the poisoning that Drug therapy is caused by the liquid that contains alcohol and/or at least a toxic component of pure succedaneum, it comprises that parenteral gives the ortho position dithioglycol of the general formula of at least a claim 1 (1).
15. according to the method that claim 13 and 14 each Drug therapys are poisoned, it comprises that the ortho position dithioglycol with the general formula of at least a claim 1 (1) is administered in portal vein and/or the umbilical vein, promptly comprises in the portal vein infusion or through the umbilicus infusion.
16., wherein realize by using peroral dosage form through enteral administration according to claim 11,12 and 13 each methods.
17., wherein realize by probe through enteral administration according to claim 12 and 13 each methods.
18. according to each the method for Drug therapy of claim 12 to 17, wherein further realize it by detoxifcation measure complex known in the art, described measure is that toxicokinetics is proofreaied and correct and/or toxicodynamics is proofreaied and correct.
19. the medicament of the poisoning that prevention is caused by the liquid that contains alcohol and/or at least a toxic component of pure succedaneum, it comprises at least a active component, it is characterized in that as at least a active component, described medicament contains the ortho position dithioglycol of the general formula (1) of claim 1.
20., it is characterized in that described medicament is formulated into the form that is suitable for oral administration according to the medicament of claim 19.
21., it is characterized in that described medicament is mixed with dosage form or non-dosage form according to the medicament of claim 20.
22. the medicament of the poisoning that Drug therapy is caused by the liquid that contains alcohol and/or at least a toxic component of pure succedaneum, it comprises at least a active component, it is characterized in that as at least a active component, described medicament contains the ortho position dithioglycol of the general formula (1) of claim 1.
23., it is characterized in that described medicament is formulated into the form that is suitable for oral administration according to the medicament of claim 22.
24., it is characterized in that described medicament is formulated into solid drug forms or liquid medicine form according to claim 22 and 23 each medicaments.
25. according to each medicament of claim 19 to 24, it additionally contains at least a following active substance that is selected from: vitamin, previtamin, vitamin derivative, organic acid, organic acid derivatives, lipid, the last activated peptide of physiology, aminoacid, amino acid derivativges, enzyme, enzyme derivative, enzyme precursor, coenzyme, coenzyme derivant, coenzyme precursors, carbohydrate, mineral, metal ion source, albumen and its mixture.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2006140889 | 2006-11-21 | ||
RU2006140889/14A RU2006140889A (en) | 2006-11-21 | 2006-11-21 | MEANS AND METHOD FOR PREVENTION AND TREATMENT OF POISONING BY ALCOHOL-CONTAINING LIQUIDS AND ALCOHOL SURROGATES |
PCT/RU2007/000640 WO2008063099A1 (en) | 2006-11-21 | 2007-11-19 | Agent and method for preventing and treating intoxication by alcohol-containing liquids and alcohol substitutes |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101594856A true CN101594856A (en) | 2009-12-02 |
CN101594856B CN101594856B (en) | 2014-06-25 |
Family
ID=39429946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200780049298.3A Expired - Fee Related CN101594856B (en) | 2006-11-21 | 2007-11-19 | Agent and method for preventing and treating intoxication by alcohol-containing liquids and alcohol substitutes |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP2010510307A (en) |
KR (1) | KR20090081434A (en) |
CN (1) | CN101594856B (en) |
EA (1) | EA018359B1 (en) |
RU (1) | RU2006140889A (en) |
WO (1) | WO2008063099A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2627610C2 (en) * | 2015-10-15 | 2017-08-09 | Общество с ограниченной ответственностью "РОСБИО" | Amino acids composition for methanol poisoning prevention and treatment |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2154997C1 (en) * | 1999-03-12 | 2000-08-27 | Чернов Виктор Николаевич | Method of treating generalized peritonitis |
RU2157647C1 (en) * | 1999-12-29 | 2000-10-20 | Зенович Сергей Михайлович | Food additive and method of preparation thereof, biologically-active food additive and method of preparation thereof, foodstuff and method of preparation thereof |
RU2423117C2 (en) * | 2003-07-02 | 2011-07-10 | Сергей Михайлович Зенович | Medication for reducing rate of progressing, prevention of development, prevention of onset of pathological processes induced by intake of ethanol and/or substances possessing addictive potential |
-
2006
- 2006-11-21 RU RU2006140889/14A patent/RU2006140889A/en not_active Application Discontinuation
-
2007
- 2007-11-19 WO PCT/RU2007/000640 patent/WO2008063099A1/en active Application Filing
- 2007-11-19 KR KR1020097012698A patent/KR20090081434A/en not_active Application Discontinuation
- 2007-11-19 EA EA200900702A patent/EA018359B1/en not_active IP Right Cessation
- 2007-11-19 JP JP2009538362A patent/JP2010510307A/en active Pending
- 2007-11-19 CN CN200780049298.3A patent/CN101594856B/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101594856B (en) | 2014-06-25 |
RU2006140889A (en) | 2008-05-27 |
JP2010510307A (en) | 2010-04-02 |
EA200900702A1 (en) | 2009-12-30 |
KR20090081434A (en) | 2009-07-28 |
EA018359B1 (en) | 2013-07-30 |
WO2008063099A1 (en) | 2008-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liepinsh et al. | Mildronate treatment alters γ-butyrobetaine and l-carnitine concentrations in healthy volunteers | |
SG175993A1 (en) | Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers | |
WO2007049818A1 (en) | Anti-fatty liver, anti-obesity or hypolipidemic composition | |
Ostojic et al. | Guanidinoacetic acid in human nutrition: Beyond creatine synthesis | |
CN101594856B (en) | Agent and method for preventing and treating intoxication by alcohol-containing liquids and alcohol substitutes | |
Ueno et al. | Metabolic contribution of hepatic autophagic proteolysis: old wine in new bottles | |
WAKAMIYA et al. | Vitamin C activity of 2-O-α-D-glucopyranosyl-L-ascorbic acid in guinea pigs | |
US20130005783A1 (en) | Prevention And Treatment Of Diseases Caused By Elevated Levels Of Deoxy-Sphingolipids | |
Durbin et al. | Pharmacodynamics and pharmacokinetics of acamprosate: an overview | |
US20080160001A1 (en) | Antihypercholesterolemic Formulation with Less Side-Effects | |
Lee et al. | Red mold rice promoted antioxidase activity against oxidative injury and improved the memory ability of zinc-deficient rats | |
RU2343911C2 (en) | Intensifying of alcohol metabolism | |
CN101652134A (en) | Drug for preventing and/or treating fatty liver or nonalcoholic fatty liver disease | |
EP3043788B1 (en) | D-glyceric acid or dl-glyceric acid for use in the treatment of degeneration diseases related to aging | |
Yamaguchi et al. | A study on the mechanism by which sodium nitroprusside, a nitric oxide donor, applied to the anteroventral third ventricular region provokes facilitation of vasopressin secretion in conscious rats | |
RU2423117C2 (en) | Medication for reducing rate of progressing, prevention of development, prevention of onset of pathological processes induced by intake of ethanol and/or substances possessing addictive potential | |
RU2329056C1 (en) | Hepatoprotector | |
AA | The Effect of L-Carnitine on Cardiac Output in Patient with Chronic Kidney Disease on Regular Hemodialysis. | |
WO2002083703A1 (en) | Composition based on a s-adenosyl-l-methionine polyphosphate and uses of such a polyphosphate | |
ALIMOVA | RENAL PARENCHYMA OF ENERGY DRINKS INFLUENCE ON MORPHO-FUNCTIONAL CHANGES | |
Pagare et al. | The antisickling agent, 5‐hydroxymethyl‐2‐furfural: Other potential pharmacological applications | |
TWI334862B (en) | ||
Ghazaryan | Molixan’s Membrane Protective Properties in Case of Acute Ethanol Intoxication | |
FR2946534A1 (en) | USE OF ALKYLGLYCEROLS FOR THE PREPARATION OF MEDICAMENTS. | |
FR3125706A1 (en) | Combination product to stimulate the functioning of liver cells and facilitate sleep |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: VALENTA CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20110613 Address after: Russian Federation Moscow Applicant after: Zenovich Sergei Mikhailovich Co-applicant after: VALENTA Co.,Ltd. Address before: Russian Federation Moscow Applicant before: Zenovich Sergei Mikhailovich |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140625 |
|
CF01 | Termination of patent right due to non-payment of annual fee |